Search results
China’s Big, Bad, Gun-Slinging Robot Dogs—and the Future of War
The Daily Beast via Yahoo News· 2 days agoIn recent military drills with Cambodia, China unleashed a slew of robotic “dogs” that are equipped...
Aptevo Participating in the BIO International Convention
Digital Journal· 1 day agoCONTACT: Miriam Weber Miller...News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today
Swirling Global Uncertainties Make It a Great Time to Be a Greek Shipowner
Bloomberg via Yahoo News· 2 days ago(Bloomberg) -- Sandwiched between the world’s great global powers in a time of deepening global...
LETTERS: Fully fund the military; reasons for distress flags
Colorado Springs Gazette· 22 hours agoPlans for possible military conflict around Taiwan conclude we would run out of needed cruise...
On-the-Record Press Gaggle by White House National Security Communications Advisor John Kirby | The...
The White House· 6 days agoToday, the Secretary of the Army is in Mesquite, Texas, for the opening of a new factory that will...
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR...
Morningstar· 6 days agoEfficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/ ...
OTR: Mass. congressman says Trump's conviction raises stakes of 2024 election
WCVB Boston· 2 days agoCONGRESSMAN SETH MOULTON IS OUR GUEST THIS MORNING. THE CONGRESSMAN IS IN THE CHAIR. AS YOU CAN SEE...
The Motley Fool: Try on Nike stock for size
Dallas Morning News· 2 days agoNike stock slumped after its third-quarter earnings report, which featured weak revenue growth and disappointing projections. The stock’s value has...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily...
Morningstar· 3 days agoIn 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ...
Veeva Announces Fiscal 2025 First Quarter Results
Yucaipa News Mirror· 5 days agoVeeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its first quarter ended ...